Clinica di Chirurgia Generale e Metodologia Chirurgica, Università Politecnica delle Marche-Ospedali Riuniti, via Conca 1, 60121, Ancona, Italy.
Surg Endosc. 2010 Oct;24(10):2542-6. doi: 10.1007/s00464-010-1000-7. Epub 2010 Mar 25.
Because the most suitable management of subclinical Cushing syndrome (SCS, which involves hypersecretion of cortisol without clinically evident disease) still is undefined, the current study aimed to compare retrospectively the outcome for a cohort of patients treated by medical therapy or laparoscopic adrenalectomy (LA).
Over a 12-year period, 47 patients with SCS have been treated by means of LA (19 patients, group A) or medical therapy (28 patients, group B). Group A consisted of 15 women and 4 men with a mean age of 54.8 years. Eight patients had a left adrenal mass, whereas nine had a right adrenal mass, and one patient had bilateral lesion. Group B was composed of 18 women and 10 men with a mean age of 57.8 years. Of these patients, 14 had a left adrenal lesion, 12 had a right adrenal lesion, and 1 had bilateral lesion. The patients were followed up for a mean 4 years (range, 1-11 years) by both an endocrinologist and a surgeon.
In group A, hypertension improved for 66.3% of the patients; body mass index (BMI) decreased for 47.4%; and hyperlipidemia based on high-density lypoproteins (HDL) cholesterol, total cholesterol ratio, and triglyceridemic concentration improved for 63.2% of the patients. No changes in bone parameters were seen after surgery in SCS patients with osteoporosis. Some patients in group B, during their long-term medical therapy, experienced worsening hypertension (14.2%), hyperlipidemia (17.8%), and diabetes mellitus (8%).
This retrospective study focused on a cohort of patients with SCS. Their medium long-term follow-up evaluation showed that LA is better than medical therapy for treating this condition, especially by reducing the cardiovascular risk (hypertension-hyperlipidemia).
由于亚临床库欣综合征(SCS,即皮质醇分泌亢进而无明显临床疾病)的最佳治疗方法尚未确定,本研究旨在回顾性比较经腹腔镜肾上腺切除术(LA)和药物治疗的患者结局。
在 12 年期间,有 47 例 SCS 患者接受了 LA(19 例,A 组)或药物治疗(28 例,B 组)。A 组由 15 名女性和 4 名男性组成,平均年龄为 54.8 岁。8 例患者存在左侧肾上腺肿块,9 例存在右侧肾上腺肿块,1 例患者存在双侧病变。B 组由 18 名女性和 10 名男性组成,平均年龄为 57.8 岁。其中 14 例患者存在左侧肾上腺病变,12 例患者存在右侧肾上腺病变,1 例患者存在双侧病变。内分泌医生和外科医生对患者进行了平均 4 年(1-11 年)的随访。
A 组中,66.3%的患者高血压得到改善;47.4%的患者体重指数(BMI)降低;63.2%的患者高密度脂蛋白胆固醇(HDL)、总胆固醇比值和三酰甘油浓度升高的高脂血症得到改善。SCS 合并骨质疏松症患者手术后骨参数无变化。B 组部分患者在长期药物治疗期间出现高血压恶化(14.2%)、高脂血症(17.8%)和糖尿病(8%)。
本回顾性研究关注了一组 SCS 患者。他们的中期随访评估表明,LA 治疗该疾病优于药物治疗,特别是可以降低心血管风险(高血压-高脂血症)。